1. At a Glance – The Smallcap That Thinks It’s a Pharma Giant
Everest Organics Ltd is sitting at a market cap of ₹282 crore with a stock price of ₹290, down 12.3% in the last 3 months and nearly 20% in a single session recently. High volatility? Of course. This is smallcap pharma — drama is included free of cost.
Trailing twelve-month sales stand at ₹188 crore with PAT of ₹5.84 crore. That’s an OPM of 8.79% and a P/E of 48.2. Industry P/E? 28.2. ROCE? 1.76%. ROE? -2.23%. Yes, negative.
Latest quarterly (Dec 2025) sales came in at ₹42.59 crore with PAT of ₹0.36 crore. Profit down 68% YoY. EPS for the quarter: ₹0.37.
Annualised EPS (Q3 method) = Average of Q1, Q2, Q3 EPS × 4
= (1.45 + 1.19 + 0.37) / 3 × 4
= 1.003 × 4 ≈ ₹4.01
At CMP ₹290, forward annualised P/E ≈ 72.
Let that sink in.
A company with 1–2% ROCE trading at 70+ earnings. Either the market sees a turnaround. Or it’s high on API fumes.
Curious already? Good. Let’s open the lab notebook.
2. Introduction – Pharma Dreams, Working Capital Nightmares
Everest Organics was incorporated in 1993. Manufacturing APIs and intermediates from Telangana. Sounds solid. APIs are serious business. High regulation. High barriers. High compliance. High headaches.
The company manufactures Omeprazole, Esomeprazole, Pantoprazole, Benzimidazole and chloro compounds. That’s gastro portfolio heavy.
Facility capacity: 820 MTPA. Utilisation? 90%+ for top products.
So capacity is running hot.
But profitability? Not exactly burning.
Over 5 years, sales growth is -0.94%. Over 3 years, -7.28%. ROE 3-year average: -0.82%.
At the same time, debtor days ballooned to 202 days. Inventory days at 166. That’s not a pharma company. That’s a storage business.
Promoter holding fell from 74% to 59.6%. That’s not small.
The founder passed away in 2022 and management shifted to Dr. Sirisha Kakarlapudi.
Meanwhile:
- Preferential issue
- Increase in authorised capital
- Director resignations
- Company secretary resignations
- Postal ballot for executive appointments
- Auditor qualifications
- TSPCB non-compliance flagged
- Interest provisioning issues flagged
This isn’t a sleepy API manufacturer.
This is a smallcap pharma thriller.
You still reading? Good.
3. Business Model – WTF Do They Even Do?
Everest Organics manufactures:
APIs (Active Pharmaceutical Ingredients)
Used in gastro, anti-diabetic, anti-fungal, anti-viral etc.
Intermediates
Omeprazole, Esomeprazole, Pantoprazole etc.
By-products
Ammonium sulphate, sodium nitrite etc.
Installed capacity at Aroor, Telangana: 820 MTPA.
Capacity split:
- Omeprazole ~215 TPA
- Chloro Compound ~480 TPA
- Benzimidazole ~250 TPA
- Esomeprazole ~144 TPA
- Pantoprazole ~60 TPA
They sell 78% domestic, 22% exports (FY22 data).
They have 60 clients across 45 countries and aim to hit 100 clients in 60 countries by FY25.
They got:
- USFDA inspection (no observations, May 2024)
- Korea DMF approval for Rabeprazole (Feb 2025)
- Filing for European, US, China DMF
So technically? Solid.
Strategically? Ambitious.
Financially? Fragile.
You tell me — which
